Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells

References

• Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev. 2006;214:130-42. doi:10.1111/j.1600-065X.2006.00460.x. PMID:17100881
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-9. doi:10.1182/blood-2007-09-077438. PMID:18650461
   PubMed Web of Science ®Google Scholar
• Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell. 2010;142:847-56. doi:10.1016/j.cell.2010.08.031. PMID:20850008
   PubMed Web of Science ®Google Scholar
• Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013;2:e26097. doi:10.4161/onci.26097. PMID:24353908
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001;98:11521-6. doi:10.1073/pnas.201238598. PMID:11562472
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413:165-71. doi:10.1038/35093109. PMID:11557981
   PubMed Web of Science ®Google Scholar
• Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002;169:4098-102. doi:10.4049/jimmunol.169.8.4098. PMID:12370336
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734-8. doi:10.1038/nature01112. PMID:12384702
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413-41. doi:10.1146/annurev-immunol-032712-095951. PMID:23298206
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008;68:6368-76. doi:10.1158/0008-5472.CAN-07-6768. PMID:18676862
   PubMed Web of Science ®Google Scholar
• Boutet P, Aguera-Gonzalez S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT, Vales-Gomez M. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol. 2009;182:49-53. doi:10.4049/jimmunol.182.1.49. PMID:19109134
   PubMed Web of Science ®Google Scholar
• Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer. 2013;133:1557-66. doi:10.1002/ijc.28174. PMID:23526433
   PubMed Web of Science ®Google Scholar
• Wolpert F, Tritschler I, Steinle A, Weller M, Eisele G. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol. 2014;16:382-91. doi:10.1093/neuonc/not232. PMID:24327582
   PubMed Web of Science ®Google Scholar
• Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6:32-43. doi:10.1038/nrm1548. PMID:15688065
   PubMed Web of Science ®Google Scholar
• Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123-34. doi:10.1038/nrc3004. PMID:21258396
   PubMed Web of Science ®Google Scholar
• Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576-90. doi:10.1016/j.ccr.2011.09.009. PMID:22094253
   PubMed Web of Science ®Google Scholar
• Placke T, Kopp HG, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 2011;3:374-82. doi:10.1159/000323936. PMID:21411974
   PubMed Web of Science ®Google Scholar
• Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968;61:46-52. doi:10.1073/pnas.61.1.46. PMID:5246932
   PubMed Web of Science ®Google Scholar
• Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104:397-401. doi:10.1182/blood-2004-02-0434. PMID:15031212
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-300. PMID:10096562
   PubMed Web of Science ®Google Scholar
• Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69:7775-83. doi:10.1158/0008-5472.CAN-09-2123. PMID:19738039
   PubMed Web of Science ®Google Scholar
• Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, Salih HR. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72:440-8. doi:10.1158/0008-5472.CAN-11-1872. PMID:22127925
   PubMed Web of Science ®Google Scholar
• Placke T, Salih HR, Kopp HG. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J Immunol. 2012;189:154-60. doi:10.4049/jimmunol.1103194. PMID:22649191
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008;27:5944-58. doi:10.1038/onc.2008.272. PMID:18836475
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A, Villa-Alvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol. 2014;5:106. doi:10.3389/fimmu.2014.00106. PMID:24711808
   PubMed Web of Science ®Google Scholar
• Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med. 2012;209:2409-22. doi:10.1084/jem.20120565. PMID:23166357
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4. doi:10.1038/35393. PMID:9468137
   PubMed Web of Science ®Google Scholar
• Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, Padovani A, Di Luca M. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology. 2004;62:498-501. doi:10.1212/01.WNL.0000106953.49802.9C. PMID:14872043
   PubMed Web of Science ®Google Scholar
• Bergmeier W, Piffath CL, Cheng G, Dole VS, Zhang Y, von Andrian UH, Wagner DD. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res. 2004;95:677-83. doi:10.1161/01.RES.0000143899.73453.11. PMID:15345652
   PubMed Web of Science ®Google Scholar
• Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, Speicher KD, Blair IA, Speicher DW, Grosser T, et al. Deciphering the human platelet sheddome. Blood. 2011;117:e15−26. doi:10.1182/blood-2010-05-283838. PMID:20962327
   PubMed Web of Science ®Google Scholar
• Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, Padovani A, Di Luca M. [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med. 2002;8:67-74. PMID: 12080182. PMID:12080182
   PubMed Web of Science ®Google Scholar
• Saftig P, Reiss K. The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol. 2011;90:527-35. doi:10.1016/j.ejcb.2010.11.005. PMID:21194787
   PubMed Web of Science ®Google Scholar
• Wiesner T, Bugl S, Mayer F, Hartmann JT, Kopp HG. Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis. 2010;27:141-9. doi:10.1007/s10585-010-9311-6. PMID:20182908
   PubMed Web of Science ®Google Scholar
• Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014;124:184-7. doi:10.1182/blood-2014-03-562538. PMID:24868077
   PubMed Web of Science ®Google Scholar
• Meyer T, Amaya M, Desai H, Robles-Carrillo L, Hatfield M, Francis JL, Amirkhosravi A. Human platelets contain and release TWEAK. Platelets. 2010;21:571-4. doi:10.3109/09537104.2010.512403. PMID:20849210
   PubMed Web of Science ®Google Scholar
• Koerner SP, Andre MC, Leibold JS, Kousis PC, Kubler A, Pal M, Haen SP, Buhring HJ, Grosse-Hovest L, Jung G, et al. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. Leukemia. 2017;31:459-69. doi:10.1038/leu.2016.194. PMID:27435001
   PubMed Web of Science ®Google Scholar
• Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006;129:2416-25. doi:10.1093/brain/awl205. PMID:16891318
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol. 2004;25:489-95. doi:10.1016/j.it.2004.07.003. PMID:15324742
   PubMed Web of Science ®Google Scholar
• Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science. 2015;348:136-9. doi:10.1126/science.1258867
   PubMed Web of Science ®Google Scholar
• Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189:1360-71. doi:10.4049/jimmunol.1200796. PMID:22730533
   PubMed Web of Science ®Google Scholar
• Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol. 2006;67:188-95. doi:10.1016/j.humimm.2006.02.008. PMID:16698441
   PubMed Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389-96. doi:10.1182/blood-2003-01-0019. PMID:12714493
   PubMed Web of Science ®Google Scholar
• Raab S, Steinbacher J, Schmiedel BJ, Kousis PC, Steinle A, Jung G, Grosse-Hovest L, Salih HR. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. J Immunol. 2014;193:4261-72. doi:10.4049/jimmunol.1400872. PMID:25217158
   PubMed Web of Science ®Google Scholar